Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
96.63%
Operating Margin
110.41%
Net Margin
97.74%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
110.41%
Income Tax Rate
0.00%
EPS
0.4900000000
Balance Sheet Analysis
Current Ratio
0.66
Cash Ratio
1.11
Working Capital
$-2.64M
Debt to Equity
0.34
Debt to Assets
24.23%
Equity Ratio
72.06%
Cash Flow Analysis
Operating Cash Flow Ratio
45.21%
Free Cash Flow Ratio
45.21%
CapEx to Revenue
0.00%
Dividends Paid
$14.13M
Stock Buybacks
No buybacks
Total Shareholder Returns
$14.13M
Cash Position Change
179.00%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
222.24%
Net Income
216.09%
EPS
213.95%
Operating Income
112.72%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-5.62%
Operating Cash Flow
5.44%
Free Cash Flow
5.44%
Balance Sheet Health
Assets
0.58%
Debt
-13.22%
Book Value per Share
8.19%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-0.13%
Shares Outstanding
0.29%
Long Term Trends
3Y Revenue/Share
134.66%
5Y Revenue/Share
663.71%
3Y Dividend/Share
-0.84%
5Y Dividend/Share
7.55%